CD47 and Parkinson disease: It enhances the stability, hydrophobicity, and aggregation potential of the Aβ peptide underlying β-amyloid formation in Alzheimer’s disease (34); it forms pGlu79-α-synuclein, which promotes oligomerization and synucleinopathies in Parkinson’s disease (35, 36); and the modification of CD47 directly influences interactions with SIRPα to modulate the immunological surveillance mechanisms essential for the removal of cancer and senescent cells (37, 38).